Tabea starts her thesis project about LIN28B in SQLC


Today Tabea has her first day in the lab. She will investigate novel therapeutic strategies for squamous cell lung carcinomas (SQLC). LIN28B expression marks a clinically relevant subgroup of patients which may benefit from anti-angiogenic therapy and immune checkpoint blockade. Welcome Tabea!

Tabea recently completed her Master of Science in Molecular Medicine in Freiburg. She has moved her residence to Cologne, supported by a temporary employee apartment that can be rented for a maximum of one year. Her project is funded by the Fritz Thyssen Foundation.

Source: Graphics have been provided by webnode.